SEOUL,
South Korea, July 10,
2024 /PRNewswire/ -- AIRS Medical, a pioneering force
in artificial intelligence (AI) and robotics for healthcare
applications, today announced the completion of its Series C
funding round, securing $20 million
from seven institutional investors in Korea. The investment, led by
BSK Investment and Shinyoung Securities, underscores confidence not
only in the company's flagship product, SwiftMR™, but also in its
larger mission to revolutionize preventive healthcare through
technology innovation.
Transforming MRI
SwiftMR™ uses deep learning technology to enhance magnetic
resonance imaging (MRI) scan speeds by as much as 50% compared to
the standard of care.* On average, radiology centers and hospitals
that integrate SwiftMR™ achieve a 38% increase in patient
throughput and a 22% reduction in business hours, leading to
$44,000 per month in additional
revenue and an $8,000 reduction in
monthly operating costs.
SwiftMR™ is a scan time reduction solution with whole
pulse-sequence coverage and true super resolution. This
cutting-edge technology has set the standard in diagnostic imaging,
helping to address critical roadblocks radiology centers and
hospitals face, such as long patient wait times and the downstream
effects of delayed diagnoses.
Improving patient outcomes
A frequent problem in healthcare is the delayed diagnosis of
patients, often after symptoms have advanced. This, along with
resource shortages, results in worse outcomes.
AIRS Medical is paving the way to detect diseases proactively,
before they manifest. Through AI and robotics, AIRS Medical is
democratizing the best diagnostics and prognostics, reducing costs
and increasing the accessibility of MRI scans. Ultimately, this
empowers patients with conditions such as dementia, stroke, and
cancer to receive early diagnoses and improve their chances of
better health.
Expanding access to care
In its quest to deliver the highest-quality preventive care to
all, AIRS Medical is rapidly expanding. Backed by a talented team,
SwiftMR™ was initially launched in Korea in 2021. By 2023, the
technology had successfully entered the
United States and Europe,
markets that now account for over half of the company's annual
recurring revenue (ARR).
"We're thrilled to receive this substantial support from our
investors," said Hyeseong Lee, CEO
of AIRS Medical. "This funding will empower us to increase access
to preventive healthcare services and create a healthier future for
people around the globe."
Building a better future
With this latest round of funding, AIRS Medical is poised to
accelerate its growth and innovate beyond the award-winning
SwiftMR™. The company plans to expand its presence in international
markets, invest in research and development, and ultimately improve
patient outcomes worldwide.
For more information about AIRS Medical, visit
https://airsmed.com/en/.
*For investigational purposes in countries outside of
the United States, South Korea, Canada, Brazil, Japan, Taiwan, Malaysia, Saudi
Arabia, UAE, Thailand,
Vietnam, and Indonesia. FDA 510(k)-cleared to support
images with scan time reduction by up to 50% in the United States.
For press inquiries or questions about this release please
contact:
Ashley Guidace
AIRS Medical
Director of Global Marketing
ashley.guidace@airsmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/airs-medical-secures-20m-in-series-c-funding-to-advance-ai-powered-preventive-healthcare-solutions-302192757.html
SOURCE AIRS Medical